Needham & Company Reiterates a 'Buy' on Celldex Therapeutics (CLDX); Five Themes Emerged That We Believe Deserve Increased Attention
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Celldex Therapeutics (NASDAQ: CLDX), PT $12.
Needham analyst says, "1) Upcoming rindopepimut pivotal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "1) Upcoming rindopepimut pivotal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
